DGAP-News: Evotec and Chinook Therapeutics enter into strategic collaboration to discover and develop novel precision medicines for chronic kidney diseases
Based on Evotec's proprietary comprehensive molecular datasets from thousands of patients across chronic kidney diseases of multiple underlying etiologies, Chinook and Evotec will jointly identify, characterise and validate novel mechanisms and discover and develop precision medicines.
DGAP-News: Evotec SE / Key word(s): Miscellaneous Evotec and Chinook Therapeutics enter into strategic collaboration to discover and develop novel precision medicines for chronic kidney diseases 01.03.2021 / 07:30 The issuer is solely responsible for the content of this announcement.
01.03.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Evotec SE |
Manfred Eigen Campus / Essener Bogen 7 | |
22419 Hamburg | |
Germany | |
Phone: | +49 (0)40 560 81-0 |
Fax: | +49 (0)40 560 81-222 |
E-mail: | [email protected] |
Internet: | www.evotec.com |
ISIN: | DE0005664809 |
WKN: | 566480 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1171812 |
End of News | DGAP News Service |
|
1171812 01.03.2021